1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
THC Farmaceuticals, Inc.

THC Farmaceuticals, Inc.

CBDG
THC Farmaceuticals, Inc.US flagOther OTC
0.02
USD
- -
- -
435,158.00Market Cap
THC Farmaceuticals, Inc.
CBDG
(Other OTC)

Recent

price

0.02

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
TTM
FRC
0.01
- -
- -
- -
- -
- -
Revenue per Share
- -
- -
- -
- -
- -
-0.01
Basic EPS, GAAP
- -
- -
- -
- -
- -
-0.11
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
-0.01
-0.01
-0.01
-0.01
Book Value per Share
0.01
- -
- -
-0.01
-0.01
0.05
Tangible Book Value per Share
5
9
9
9
9
14
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
-9.72
-69.52
-76.96
-90.5
-126.18
-379.02
Operating Margin (%)
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-22.07
-83.02
-129.8
-110.15
-161.27
-392.19
Profit Margin (%)
- -
- -
- -
- -
- -
- -
Working Capital
- -
- -
- -
- -
- -
1
LT Debt
- -
- -
- -
- -
- -
1
Total Equity
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'15
Mar'15
Jun'15
ST Debt
- -
- -
- -
LT Borrowings
- -
1
1
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
12
12
12
Market Capitalization
13
10
7

Working Capital

FRC

•

in mil. unless spec.
Dec'15
Mar'15
Jun'15
Total Current Assets
- -
1
- -
Cash, Cash Equivalents & STI
- -
1
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
- -
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
177.25%
Free Cash Flow
- -
- -
-1.61%
Net Income, GAAP
- -
- -
28.78%
Sales/Revenue/Turnover
- -
- -
-12.04%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
No data availableFinancial data will appear here once available
Similar Companies
Chengdu Olymvax Biopharmaceuticals Inc. (688319.SS)
Poltreg S.A. (PTG.WA)
Neovacs S.A. (ALNEV.PA)
AVAX Technologies, Inc. (AVXT)
Universal Ibogaine Inc. (IBO.V)
Adocia S.A. (ADOIF)
Business
THC Farmaceuticals, Inc. (CBDG) engages in the research, development, and commercialization of cannabis-based pharmaceutical products and formulations. The company, through its subsidiary CBDual Biotechnology Corp., develops cannabidiol (CBD) and tetrahydrocannabinol (THC)-based therapeutics; unique cannabis formulations, edibles, and advanced delivery systems; cannabis extract products manufactured from cannabis flower; and clinical trial access for new medical cannabis medications, therapies, and products. It also conducts research on psilocybin formulations involving genetic testing and micro-dosing protocols. Founded in 2005 and headquartered in Thousand Oaks, California, with manufacturing facilities in Southern California, THC Farmaceuticals targets the medical cannabis sector, including biotechnology and pharmaceutical applications for patients and clinical participants, primarily in the United States. Recent activities include ongoing emphasis on psilocybin research for clinical trials and maintenance of its OTC Markets listing under CBDG, with operations reflecting a market capitalization of approximately $0.6 million as of mid-2025.